Actively Recruiting
Acetyl-leucine in Post-stroke Ataxia
Led by Kafrelsheikh University · Updated on 2025-12-10
200
Participants Needed
1
Research Sites
33 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Along with the current clinical trial, the efficacy and safety of 4 gram of acetyl-leucine daily for three months in patients with post-stroke ataxia following posterior-circulation ischaemic stroke assessed through BBS, SARA, and mRS, and possible adverse effects.
CONDITIONS
Official Title
Acetyl-leucine in Post-stroke Ataxia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 80 years
- First-ever posterior-circulation ischemic stroke
- Presenting with gait ataxia
- Score at least 1 point on gait, stance, trunk, or heel-shin-slide items of the Scale for the Assessment and Rating of Ataxia (SARA)
- Score 47 points or less on the Berg Balance Scale (BBS)
- Randomization within 24 hours of stroke symptom onset or from last known normal for wake-up stroke patients
You will not qualify if you...
- Modified Rankin Scale (mRS) score of 5 or higher
- Physical or mental conditions preventing safe participation or affecting outcome assessments (e.g., dementia, disturbed consciousness, severe aphasia)
- History of neurological diseases with recurrent deficits (e.g., epilepsy, multiple sclerosis, head trauma with lasting problems)
- Intravenous thrombolysis or revascularization procedures during the first week of trial
- Recurrent ischemic stroke based on clinical or MRI findings
- Hypersensitivity to study treatment
- Organ failure (renal or liver failure), active cancer
- Known bleeding disorders, recent intracerebral hemorrhage, gastrointestinal bleeding within 6 months, or major surgery within 30 days before randomization
- Pregnant or breastfeeding women
- Cerebral venous thrombosis
- Stroke associated with cardiac arrest
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt, 33511
Actively Recruiting
Research Team
M
Mohamed G. Zeinhom, MD
CONTACT
S
Sherihan rezk Ahmed, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here